Lito, Piro

Publications

Sort by

Co-Author Network

selected publications

BRAF^V600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. 2025 GET IT
KRAS Oncoprotein Signaling in Cancer. The New England journal of medicine. 2025 Academic Article GET IT
Times cited: 3
Preclinical Evaluation of [¹²⁴I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors. ACS pharmacology & translational science. 2024 Academic Article GET IT
Times cited: 1
Pharmacological restoration of GTP hydrolysis by mutant RAS. Nature. 2024 Academic Article GET IT
Times cited: 16
RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024 Academic Article GET IT
Times cited: 34
Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell reports. Medicine. 2024 Academic Article GET IT
Times cited: 12
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF^V600E lung adenocarcinoma. Cell reports. Medicine. 2024 Academic Article GET IT
Times cited: 4
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024 Academic Article GET IT
Times cited: 159
Insights into how adeno-squamous transition drives KRAS inhibitor resistance. Cancer cell. 2024 Academic Article GET IT
Times cited: 5
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. Future oncology (London, England). 2023 Article GET IT
Times cited: 1
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer. The oncologist. 2023 Academic Article GET IT
Times cited: 8
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science (New York, N.Y.). 2023 Academic Article GET IT
Times cited: 146
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer. JCO precision oncology. 2023 Academic Article GET IT
Times cited: 42
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023 Academic Article GET IT
Times cited: 319
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
Times cited: 103
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nature medicine. 2022 Academic Article GET IT
Times cited: 119
The KRYSTAL-1 study of adagrasib - a new trial for KRAS^G12C-mutated non-small-cell lung cancer. Nature reviews. Clinical oncology. 2022 Comment GET IT
Times cited: 1
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Comment GET IT
Times cited: 1
With one eye on the future. Cancer cell. 2022 Academic Article GET IT
Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers. British journal of cancer. 2021 Academic Article GET IT
Times cited: 22
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO clinical and research reports. 2021 Academic Article GET IT
Times cited: 10
Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021 Academic Article GET IT
Times cited: 304
The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science (New York, N.Y.). 2021 Academic Article GET IT
Times cited: 56
Acquired Resistance to KRAS^G12C Inhibition in Cancer. The New England journal of medicine. 2021 Academic Article GET IT
Times cited: 806
KRAS ^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 32
Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 97
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors. Cancer discovery. 2021 Comment GET IT
Times cited: 15
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell. 2020 Review GET IT
Times cited: 179
KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors. The New England journal of medicine. 2020 Academic Article GET IT
Times cited: 1362
COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 213
Quest for Clinically Effective RAF Dimer Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 3
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020 Academic Article GET IT
Times cited: 395
The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. 2019 GET IT
Times cited: 647
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 40
A treatment strategy for KRAS-driven tumors. Nature medicine. 2018 Comment GET IT
Times cited: 14
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 380
An approach to suppress the evolution of resistance in BRAF^V600E-mutant cancer. Nature medicine. 2017 Academic Article GET IT
Times cited: 133
Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 2
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical lung cancer. 2016 Academic Article GET IT
Times cited: 133
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 555
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 119
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer cell. 2014 Academic Article GET IT
Times cited: 256
Tumor adaptation and resistance to RAF inhibitors. Nature medicine. 2013 Review GET IT
Times cited: 380
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 458
Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. The American journal of the medical sciences. 2009 Academic Article GET IT
Times cited: 12
Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts. The Journal of biological chemistry. 2008 Academic Article GET IT
Times cited: 21
Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts. The Journal of biological chemistry. 2007 Academic Article GET IT
Times cited: 29

more ...

less ...

Background

education and training

B.S., Michigan State University 2001
M.D., Michigan State University, College of Human Medicine 2008
Ph.D., Michigan State University 2006

Contact

full name

Piro Lito

VIVO Weill Cornell Medical College

Piro Lito Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name